ELTX Elicio Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ELTX matters now
Elicio Therapeutics, Inc. (ELTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.48 with -0.29% on the session and $66.4M in market capitalization; recent performance reads 1-month -58.02% and YTD -51.63%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-11.8M, and EPS of $-0.65. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.4%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Haqq Christopher filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-48.79
P/S
0.00
EV/EBITDA
-1.93
DCF Value
$0.22
FCF Yield
-52.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-2748.2%
ROA
-177.1%
ROIC
-227.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-11.8M | $-0.65 |
| Q4 2025 | $0.00 | $-7.7M | $-0.45 |
| FY 2025 | $0.00 | $-39.6M | $-2.58 |
| Q3 2025 | $0.00 | $-10.1M | $-0.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$17.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.14
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.